Overview

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Status:
Not yet recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

Summary

Although studies are ongoing to evaluate the efficiency and safety of venetoclax-based therapy, alone or in combination with hypomethylation agent or low-dose cytarabine, in relapsed/refractory acute myeloid leukemia, data are scarce and heterogenous. In this study, the investigators aimed to assess safety and response to a new venetoclax-based triple-drug combination regimen (venetoclax + hypomethylation agent + low-dose cytarabine) in acute myeloid leukemia patients who had relapsed/refractory disease or positive minimal residual disease.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing 302 Hospital

Treatments:

Azacitidine
Cytarabine
Decitabine
Venetoclax